Molecular biology reports · 2026
Protective effects of Bacillus clausii in cyclophosphamide-induced immunosuppression and intestinal mucositis in rats: histopathological and inflammatory evaluation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ekinci Gencay, Daldaban Fadime, Tüfekçi Emre, Yıldız Gülce, Balcıoğlu Esra, Akyüz Bilal, Güneş Vehbi, Arslan Korhan
Аннотация
BACKGROUND: Bacillus clausii (B. clausii) is a Gram-positive, spore-forming probiotic widely used for the prevention and treatment of gastrointestinal disorders and may have protective effects against chemotherapy-induced intestinal mucositis. Cyclophosphamide (CP) can induce immunosuppression and intestinal mucosal injury, leading to inflammation and alterations in intestinal homeostasis. This study evaluated the protective effects of B. clausii on intestinal histopathology, inflammation, pro-inflammatory cytokines, and miR-146a expression in a rat model of CP-induced immunosuppression and intestinal mucositis.
METHODS AND RESULTS: Thirty-two male Wistar albino rats were randomly allocated into four groups: Group 1 (Control), Group 2 (CP + saline), Group 3 (saline + B. clausii), and Group 4 (CP + B. clausii). Immunosuppression and intestinal mucositis were induced by intraperitoneal CP administration, followed by oral B. clausii treatment. Clinical findings, hematological parameters, histopathology, histomorphometry, cytokine levels, and gene expression were assessed. CP administration impaired body weight gain, altered stool consistency, reduced leukocyte and lymphocyte counts, and caused intestinal mucosal injury with villus shortening, epithelial disruption, inflammatory infiltration, fibrosis, and goblet cell depletion. Villus length decreased by 10.58% and goblet cell count by 44.20% in Group 2 compared with Group 1 (P < 0.001). In Group 4, villus length and goblet cell count increased by 17.81% and 66.34%, respectively, compared with Group 2 (P < 0.001). B. clausii also improved stool consistency, partially restored leukocyte parameters, preserved mucosal architecture, and reduced inflammatory infiltration and fibrosis. Furthermore, B. clausii attenuated CP-induced increases in TNF-α and IL-6, whereas miR-146a expression remained reduced in CP-treated groups.
CONCLUSIONS: B. clausii partially attenuated cyclophosphamide-induced intestinal mucositis by improving clinical and histopathological findings, preserving intestinal morphology, restoring goblet cell numbers, and reducing TNF-α and IL-6 levels. The partial recovery of leukocyte and lymphocyte counts suggests potential immunomodulatory effects. Although miR-146a expression was reduced in CP-treated groups, the mechanisms underlying the protective effects of B. clausii remain unclear. Overall, B. clausii may represent a promising supportive probiotic approach for mitigating chemotherapy-induced intestinal mucosal injury. Further mechanistic and clinical studies are warranted to clarify its effects on miR-146a, the intestinal microbiota, inflammatory pathways, and intestinal barrier function.
METHODS AND RESULTS: Thirty-two male Wistar albino rats were randomly allocated into four groups: Group 1 (Control), Group 2 (CP + saline), Group 3 (saline + B. clausii), and Group 4 (CP + B. clausii). Immunosuppression and intestinal mucositis were induced by intraperitoneal CP administration, followed by oral B. clausii treatment. Clinical findings, hematological parameters, histopathology, histomorphometry, cytokine levels, and gene expression were assessed. CP administration impaired body weight gain, altered stool consistency, reduced leukocyte and lymphocyte counts, and caused intestinal mucosal injury with villus shortening, epithelial disruption, inflammatory infiltration, fibrosis, and goblet cell depletion. Villus length decreased by 10.58% and goblet cell count by 44.20% in Group 2 compared with Group 1 (P < 0.001). In Group 4, villus length and goblet cell count increased by 17.81% and 66.34%, respectively, compared with Group 2 (P < 0.001). B. clausii also improved stool consistency, partially restored leukocyte parameters, preserved mucosal architecture, and reduced inflammatory infiltration and fibrosis. Furthermore, B. clausii attenuated CP-induced increases in TNF-α and IL-6, whereas miR-146a expression remained reduced in CP-treated groups.
CONCLUSIONS: B. clausii partially attenuated cyclophosphamide-induced intestinal mucositis by improving clinical and histopathological findings, preserving intestinal morphology, restoring goblet cell numbers, and reducing TNF-α and IL-6 levels. The partial recovery of leukocyte and lymphocyte counts suggests potential immunomodulatory effects. Although miR-146a expression was reduced in CP-treated groups, the mechanisms underlying the protective effects of B. clausii remain unclear. Overall, B. clausii may represent a promising supportive probiotic approach for mitigating chemotherapy-induced intestinal mucosal injury. Further mechanistic and clinical studies are warranted to clarify its effects on miR-146a, the intestinal microbiota, inflammatory pathways, and intestinal barrier function.